Progress beyond the state of the art
InterLynk advanced regenerative medicine by developing xeno-free, photopolymerizable platelet lysate (PL)-based biomaterials with tunable mechanical and biological properties. Six inks were created, from pristine PLMAdn hydrogels to ceramic- and drug-enriched composites, enabling integration of bioactive human-derived matrices with structural ceramics in multimaterial scaffolds.
A hybrid 3D additive manufacturing workflow combined a TRL 8 Print&Cure head with electrospinning/melt electrowriting modules on a single platform, enabling spatially organized multimaterial constructs. An in silico framework linking scaffold architecture, patient imaging, and mechano-biological response was validated in mandibular and femoral models.
Early in vivo and eHTA results confirmed safety, biocompatibility, scalability, and strong clinical translation potential.
Expected results until project end
InterLynk will validate multimaterial scaffolds in critical-sized defect models, finalize sustainability and scalability guidelines for PL-based products, and consolidate business plans.
The lead product — a 10×10×10 mm PLMAdn bone augmentation scaffold — is expected to reach readiness for pre-clinical development, supported by a defined regulatory pathway and industrial-scale production strategy.
Potential impacts
Clinically, PLMAdn scaffolds may reduce reliance on autografts and allografts, lowering morbidity, rehabilitation time, and infection risks.
Economically, scalable manufacturing and competitive pricing (~90€ per device) position the solution as a cost-effective option for dental clinics, targeting ~70,000 annual procedures in Germany alone.
Industrial outcomes include a biomaterial platform, upgraded 3D-bioprinting capabilities, and digital dissemination tools, reinforcing Europe’s leadership in biofabrication.
Wider societal implications
By delivering safer, personalized, and sustainable biomaterials, InterLynk supports EU health innovation and eco-efficiency objectives. Expanding from rare TMJ cases to widely applicable bone augmentation maximizes public health impact and accelerates accessibility.
Policy relevance
InterLynk aligns with EU priorities in advanced materials and contributes to the objectives of the Towards an Advanced Materials Act initiative. The project demonstrates how multidisciplinary integration — spanning materials science, engineering, biology, clinical expertise, modelling, industry, and regulatory assessment — accelerates safe and scalable innovation.
By combining multimaterial manufacturing, pre-clinical validation, sustainability, and market readiness, InterLynk reduces technological and regulatory risks, shortens translation timelines, and strengthens Europe’s strategic autonomy in health-related advanced materials.
The project supports future implementation of the Advanced Materials Act by positioning collaborative research as a driver of competitiveness, resilience, and responsible innovation in the EU.
